1. van den Bogaard A.E., Stobberingh E.E.. Antibiotic usage in animals: impact on bacterial resistance and public health. Drugs 58(4):1999 Oct;589-607.
2. Cho S.H., Lim Y.S., Park M.S.. Prevalence of antibiotic resistance in
Escherichia coli fecal isolates from healthy persons and patients with diarrhea. Osong Public Health Res Perspect 2(1):2011 Jun;41-45.
3. Cho S.H., Lim Y.S., Kang Y.H.. Comparison of antimicrobial resistance in
Escherichia coli strains isolated from healthy poultry and swine farm workers using antibiotics in Korea. Osong Public Health Res Perspect 3(3):2012 Sep;151-155.
4. Shin H.H., Cho S.H.. Prevalence of antimicrobial resistance in
Escherichia coli strains isolated from fishery workers. Osong Public Health Res Perspect 4(2):2013 Apr;72-75.
5. Peirano G., Sang J.H., Pitondo-Silva A.. Molecular epidemiology of extended-spectrum-β-lactamase-producing
Klebsiella pneumoniae over a 10 year period in Calgary, Canada. J Antimicrob Chemother 67(5):2012 May;1114-1120.
6. Van der Bij A.K., Peirano G., Goessens W.H.. Clinical and molecular characteristics of extended-spectrum-beta-lactamase-producing
Escherichia coli causing bacteremia in the Rotterdam area, Netherlands. Antimicrobial Agents Chemother 55(7):2011 Jul;3576-3578.
7. Burgess D.S., Hall R.G. 2nd, Lewis J.S. 2nd. Clinical and microbiologic analysis of a hospital’s extended-spectrum β-lactamase-producing isolates over a 2-year period. Pharmacotherapy 23(10):2003 Oct;1232-1237.
8. Bonnet R.. Growing group of extended-spectrum β-lactamases: the CTX-M enzymes. Antimicrobial Agents Chemother 48(1):2004 Jan;1-14.
9. Livermore D.M., Canton R., Gniadkowski M.. CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother 59(2):2007 Feb;165-174.
10. Paterson D.L., Hujer K.M., Hujer A.M.. Extended-spectrum β-lactamases in
Klebsiella pneumoniae bloodstream isolates from seven countries: dominance and widespread prevalence of SHV- and CTX-M-type β-lactamases. Antimicrobial Agents Chemother 47(11):2003 Nov;3554-3560.
11. Pitout J.D.D., Church D.L., Gregson D.B.. Molecular epidemiology of CTX-M-producing
Escherichia coli in the Calgary Health Region: emergence of CTX-M-15-producing isolates. Antimicrobial Agents Chemother 51(4):2007 Apr;1281-1286.
12. Valverde A., Coque T.M., Sánchez-Moreno M.P.. Dramatic increase in prevalence of fecal carriage of extended-spectrum β-lactamase-producing
Enterobacteriaceae during nonoutbreak situations in Spain. J Clin Microbiol 42(10):2004 Oct;4769-4775.
13. Bauernfeind A., Grimm H., Schweighart S.. A new plasmid cefotaximase in a clinical isolate of
Escherichia coli. Infection 18(5):1990 Sep–Oct;294-298.
14. Edelstein M., Pimkin M., Palagin I.. Prevalence and molecular epidemiology of CTX-M extended-spectrum β-lactamase producing
Escherichia coli and
Klebsiella pneumoniae in Russian hospitals. Antimicrobial Agents Chemother 47(12):2003 Dec;3724-3732.
15. Edelstein M., Pimkin M., Dmitrachenko T.. Multiple outbreaks of nosocomial salmonellosis in Russia and Belarus caused by a single clone of
Salmonella enterica serovar Typhimurium producing an extended-spectrum β-lactamase. Antimicrobial Agents Chemother 48(8):2004 Aug;2808-2815.
16. Pai H., Choi E.H., Lee H.J.. Identification of CTX-M-14 extended-spectrum beta-lactamase in clinical isolates of
Shigella sonnei,
Escherichia coli, and
Klebsiella pneumoniae in Korea. J Clin Microbiol 39(10):2001 Oct;3747-3749.
17. Bae I.K., Lee Y.N., Hwang H.Y.. Emergence of CTX-M-12 extended-spectrum β-lactamase-producing
Escherichia coli in Korea. J Antimicrob Chemother 58(6):2006 Dec;1257-1259.
18. Clinical and Laboratory Standards Institute (CLSI) . Performance standards for antimicrobial susceptibility testing. Twenty-Second Informational Supplement. CLSI Document M100-MS19. 2012. CLSI; Wayne, PA:
19. Park S.H., Choi S.M., Lee D.G.. Emergence of extended-spectrum β-lactamase-producing
Escherichia coli as a cause of community-onset bacteremia in South Korea: risk factors and clinical outcomes. Microb Drug Resist 17(4):2011 Dec;537-544.
20. Chung H.C., Lai C.H., Lin J.N.. Bacteremia caused by extended-spectrum-β-lactamase-producing
Escherichia coli sequence type ST131 and non-ST131 clones: comparison of demographic data, clinical features, and mortality. Antimicrobial Agents Chemother 56(2):2012 Feb;618-622.
21. Rodríguez-Baño J., Alcalá J.C., Cisneros J.M.. Community infections caused by extended-spectrum beta-lactamase-producing
Escherichia coli. Arch Intern Med 168(17):2008 Sep 22;1897-1902.
22. Peirano G., van der Bij A.K., Gregson D.B.. Molecular epidemiology over an 11-year period (2000 to 2010) of extended-spectrum β-lactamase-producing
Escherichia coli causing bacteremia in a centralized Canadian region. J Clin Microbiol 50(2):2012 Feb;294-299.